UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered under Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value HALO The NASDAQ Stock Market, LLC For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Jessica Fye - JPMorgan David Risinger - SVB Securities Jason Butler - JMP Corinne Jenkins - Goldman Sachs Operator Good afternoon. My name is Shantou, and I will b ...

Halozyme Confidential and Proprietary Third Quarter 2022 Financial and Operating Results Nasdaq: HALO November 8, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestone ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Mike DiFiore - Evercore Corinne Jenkins - Goldman Sachs David Risinger - SVB Securities Jessica Fye - JPM Chase Operator Good afternoon. My name is Rex, and I will be your conference operator toda ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mike DiFiore - Evercore Corinne Jenkins - Goldman Sachs Jessica Fye - JPM Chase Anita Dushyanth - Berenberg Capital Markets Operator Good afternoon. My name is Emma, and I will be your conference operator today. At this time, I would l ...

First Quarter 2022 Financial Results Presentation May 10, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestones and royalties), operating income, and earnings-per-sha ...

antares making medicines better" C Investor Presentation NASDAQ: ATRS | March 2022 Safe Harbor Statement & Non-GAAP Metrics This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Compa ...

Antares Pharma, Inc. (ATRS) Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants Tram Bui - VP-Corporate Communications and IR Bob Apple - President and CEO Joe Renda - SVP-Commercial Peter Richardson - EVP -Research and Development and Chief Medical Officer Fred Powell - EVP and CFO Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Stacy Ku - Cowen and Company Matt Kaplan - Ladenburg Thalmann Greg Fraser - Truist Securities Operator Ladies a ...

4Q and FY 2021 Financial and Operating Results NASDAQ: ATRS | March 3, 2022 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company's ability to achieve th ...

Halozyme Confidential and Proprietary 40th Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2022 Halozyme Confidential and Proprietary 2 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including financial estimates for 2021 and outlook for 2022) and expectations for ...